These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10522695)

  • 1. Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
    Patel M; Ko SS; McHugh RJ; Markwalder JA; Srivastava AS; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Seitz SP
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2805-10. PubMed ID: 10522695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
    Patel M; McHugh RJ; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3221-4. PubMed ID: 10576692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
    Cocuzza AJ; Chidester DR; Cordova BC; Jeffrey S; Parsons RL; Bacheler LT; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 2001 May; 11(9):1177-9. PubMed ID: 11354371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
    Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
    Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
    Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
    J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
    Cocuzza AJ; Chidester DR; Cordova BC; Klabe RM; Jeffrey S; Diamond S; Weigelt CA; Ko SS; Bacheler LT; Erickson-Viitanen SK; Rodgers JD
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1389-92. PubMed ID: 11378361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical process evolution of efavirenz, a potent non-nucleosidal HIV reverse transcriptase inhibitor.
    Chen CY; Tan L
    Enantiomer; 1999; 4(6):599-608. PubMed ID: 10672461
    [No Abstract]   [Full Text] [Related]  

  • 11. [HIV-1 polymorphism and development of resistance mutations against non-nucleoside reverse transcriptase inhibitor, efavirenz].
    Gatanaga H
    Jpn J Antibiot; 2005 Feb; 58(1):99-104. PubMed ID: 15847224
    [No Abstract]   [Full Text] [Related]  

  • 12. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Zhou T; Xie L
    Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
    [No Abstract]   [Full Text] [Related]  

  • 13. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
    Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
    Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
    Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
    J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
    Famiglini V; Silvestri R
    Molecules; 2016 Feb; 21(2):. PubMed ID: 26891289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones.
    Boechat N; Kover WB; Bongertz V; Bastos MM; Romeiro NC; Azevedo ML; Wollinger W
    Med Chem; 2007 Nov; 3(6):533-42. PubMed ID: 18045202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.
    Markwalder JA; Christ DD; Mutlib A; Cordova BC; Klabe RM; Seitz SP
    Bioorg Med Chem Lett; 2001 Mar; 11(5):619-22. PubMed ID: 11266155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.